Thrombolytic therapy for acute stroke - Not a moment to lose

New England Journal of Medicine

Volumn 359, Issue 13, 2008, Pages 1393-1395

  Lyden, Patrick ^a,b  

^a VA SAN DIEGO HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO;

BRAIN HEMORRHAGE; BRAIN INFARCTION; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG TREATMENT FAILURE; EDITORIAL; FIBRINOLYTIC THERAPY; HUMAN; METHODOLOGY; MORTALITY; PRIORITY JOURNAL; RISK FACTOR; STROKE; THERAPY DELAY; TREATMENT OUTCOME;

EID: 52649115918     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMe0806335     Document Type: Editorial

References (17)

1. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-8.
2. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med 2008;359:1317-29.
3. Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004;363:768-74.
4. Marler JR, Tilley BC, Lu M, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA Stroke Study. Neurology 2000;55:1649-55.
5. Saver JL. Time is brain - quantified. Stroke 2006;37:263-6.
6. Sattin JA, Olson SE, Liu L, Raman R, Lyden PD. An expedited code stroke protocol is feasible and safe. Stroke 2006;37:2935-9.
7. Adams HP Jr, del Zoppo G, Alberts MJ, et al. Guidelines for the early management of adults with ischemic stroke: a guideline from the American Heart Association/American Stroke Association Stroke Council, Clinical Cardiology Council, Cardiovascular Radiology and Intervention Council, and the Atherosclerotic Peripheral Vascular Disease and Quality of Care Outcomes in Research Interdisciplinary Working Groups: the American Academy of Neurology affirms the value of this guideline as an educational tool for neurologists. Stroke 2007;38:1655-711. [Errata, Stroke 2007;38(6):e38, 38(9):e96.]
8. Generalized efficacy of t-PA for acute stroke: subgroup analysis of the NINDS t-PA Stroke Trial. Stroke 1997;28:2119-25.
9. Graham GD. Tissue plasminogen activator for acute ischemic stroke in clinical practice: a meta-analysis of safety data. Stroke 2003;34:2847-50.
10. Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study. Lancet 2007;369:275-82. [Erratum, Lancet 2007;369:826.]
11. Lyden PD. Thrombolytic therapy for acute stroke. 2nd ed. Totowa, NJ: Humana Press, 2005.
12. Alexandrov AV, Grotta JC. Arterial reocclusion in stroke patients treated with intravenous tissue plasminogen activator. Neurology 2002;59:862-7.
13. Tilley BC, Marler J, Geller NL, et al. Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke 1996;27:2136-42.
14. Adams HP Jr, Kenton EJ III, Scheiber SC, Juul D. Vascular neurology: a new neurologic subspecialty. Neurology 2004;63:774-6.
15. Barber PA, Zhang J, Demchuk A, Hill MD, Buchan AM. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology 2001;56:1015-20.
16. California Acute Stroke Pilot Registry (CASPR) Investigators. Prioritizing interventions to improve rates of thrombolysis for ischemic stroke. Neurology 2005;64:654-9.
17. Alberts MJ, Hademenos G, Latchaw RE, et al. Recommendations for the establishment of primary stroke centers. JAMA 2000;283:3102-9.